echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Gen: inventory of 16 cancer immunotherapy giants and R & D product lines

    Gen: inventory of 16 cancer immunotherapy giants and R & D product lines

    • Last Update: 2015-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Xinkangjie, April 16, 2015, "we believe that in 10 years, tumor immunotherapy will become the backbone of cancer management in all developed countries, accounting for 60% of the share, driven by the mode conversion of overall improvement of survival rate that resonates with patients." In recent years, tumor immunotherapy has emerged as a "sweet spot" (the best opportunity) in the eyes of researchers, companies, investment institutions, especially patients "By 2023, this area will bring more than $35 billion in potential revenue opportunities to the biopharmaceutical industry," predicted Andrew s Baum, global head of healthcare at Citibank in 2013 "We believe that in 10 years, tumor immunotherapy will become the backbone of cancer management in all developed countries, accounting for 60% of the total share, driven by the mode conversion of overall improvement of survival rate that resonates with patients." Therefore, this is also the first time Gen has launched the list, summarizing the "Sweet 16" of pharmaceutical companies rooted in the field of tumor immunotherapy, so as to show the pharmaceutical companies that are most successful in transforming the immune system into weapons for tumors Two of the most popular companies are highlighted in the list: biotechnology companies, which have spent years searching for new blockbuster drugs because old drugs are threatened by patent cliffs; and professional biotechnology companies, which have closely followed immunotherapy and used their findings to enter lucrative cooperative deals 。 It is also worth mentioning that there is no successful route at present Although some of the top cancer immunotherapy R & D companies have established compounds in their R & D pipelines, others have been successful in smaller R & D pipelines, and have won numerous clinical trials, mainly to build their own products into the successful combination therapy methods At the same time, some companies are focusing on building partnerships and partnerships rather than developing products through their own clinical trials As for the value of tumor immunotherapy research and development, we can use this military metaphor to illustrate that the first person to rush to the beach does not always mean that he can win the war The first approved tumor immunotherapy drug in the world is sipuleucel-t, Provenge, which was approved by the FDA in 2010 But years of commercial challenges forced dandelion to file for Chapter 11 bankruptcy protection on November 10 last year In February, dandelion and its sipuleucel-t and Provenge were pocketed by Valeant for $400 million Top 16 global cancer R & D Enterprises
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.